Your fact-checks will appear here
Trials of L-serine for ALS and early-stage Alzheimer’s disease/mild cognitive impairment
Reporting reviewed contains no substantive corporate history or announced research pipeline for a company named “” prior to any association with ; the only direct coverage found about Neurocept is con...
A small, investigator‑initiated Phase I ALS safety trial and at least one registered Phase IIa trial for early‑stage Alzheimer’s disease / mild cognitive impairment are recorded in the public literatu...
Dr. Paul Alan Cox’s public record shows an extensive body of peer‑reviewed publications and frequent presentations that consistently emphasize ethnobotanical drug discovery and neurodegenerative disea...